We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety.
In 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa®(riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking for patients suffering from progressive keratoconus and corneal ectasia following refractive surgery. Cross-linking is a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.
The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.